The discovery of the antibiotic penicillin in the 1920s made a big impact on human history
The discovery of the antibiotic Penicillin in the 1920s made a big impact on human history. Not only did it provide a cure for bacterial infections that were once deadly, but it also led to a golden age in discovery of new antibiotics. The great benefit of these drugs is that antibiotics inhibit the growth of bacterial cells or kill them outright, and yet, on the whole, do not harm eukaryotic cells.
This paper will explore how different antibiotics target bacterial cells without harming human cells, based on the differences between prokaryotic and eukaryotic cells. Additionally, it will explain why antibiotics are ineffective against viral infections, considering their mechanisms of action and the fundamental differences between bacteria and viruses.
How antibiotics target bacteria without harming human cells
Antibiotics exert their effects by exploiting the structural and biochemical differences between bacterial (prokaryotic) and human (eukaryotic) cells. These differences provide selective targets that antibiotics can act upon, minimizing harm to human tissues.
One classic target of antibiotics is the bacterial cell wall synthesis pathway. For example, penicillins and cephalosporins inhibit enzymes involved in peptidoglycan cross-linking (Barker & Soares, 2014). Peptidoglycan is a vital component of bacterial cell walls but is absent in human cells, which lack cell walls entirely. By disrupting cell wall synthesis, these antibiotics cause bacterial cells to lyse due to osmotic pressure, while human cells remain unaffected because they do not have peptidoglycan or similar structures.
Another target is bacterial protein synthesis. Aminoglycosides (like streptomycin) and tetracyclines inhibit bacterial ribosomes, which are structurally different from human ribosomes. Bacterial ribosomes are 70S in size, composed of 50S and 30S subunits, whereas human ribosomes are 80S with different structural properties (Wilson & Walker, 2020). This difference allows antibiotics to selectively inhibit bacterial protein synthesis without impacting human cells, reducing toxicity.
Additionally, some antibiotics target bacterial DNA replication and repair. Fluoroquinolones, such as ciprofloxacin, inhibit bacterial DNA gyrase and topoisomerase IV—enzymes essential for bacterial DNA replication. These enzymes are sufficiently different from their human counterparts, allowing selective inhibition (Hooper & Jacoby, 2016). Because human cells either do not have these enzymes or have
significantly different versions, fluoroquinolones do not significantly interfere with human DNA processes, limiting collateral damage.
Furthermore, bacterial metabolic pathways, such as folic acid synthesis, offer selective targets. Sulfonamides and trimethoprim inhibit bacterial enzymes involved in folate synthesis, a pathway absent in humans who acquire folate through their diet. This selectivity permits the drugs to inhibit bacterial growth with minimal effects on human cells (Levy, 2011).
Why antibiotics are ineffective against viruses
Antibiotics are generally ineffective against viruses due to fundamental differences in their biology and structural components. While bacteria possess cell walls, their own ribosomes, and metabolic pathways that are unique or sufficiently different from human cells, viruses lack many features targeted by antibiotics. Viruses are simply genetic material encased in a protein coat, with no cell wall or metabolic pathways of their own.
Since antibiotics target features such as bacterial cell walls, ribosomes, and DNA gyrase, these features are absent in viruses. For example, viral replication depends on hijacking host cellular machinery—such as human ribosomes—to produce viral proteins, making it impossible for antibiotics targeting bacterial components to disrupt viral processes effectively (Cruickshank et al., 2013).
Moreover, viruses lack metabolic pathways and structural elements that antibiotics typically inhibit. Without bacterial cell walls or unique enzymes like gyrase, antibiotics cannot inhibit viruses without damaging host cells. Therefore, antiviral drugs must target other aspects of viral life cycles, such as entry inhibitors, reverse transcriptase inhibitors, or protease inhibitors, which are specific to viral enzymes and processes.
In conclusion, the success of antibiotics hinges on their ability to exploit differences between bacterial and human cells. Their inability to target viruses stems from fundamental structural and biochemical differences, which is why viral infections require different treatment strategies that specifically target viral components or life cycle stages.
References
Barker, J., & Soares, S. (2014). Antibiotics and their mechanisms of action. *Clinical Microbiology Reviews*, 27(1), 252-275.
Cruickshank, R., et al. (2013). Antiviral strategies for treating viral infections. *International Journal of Antimicrobial Agents*, 42(6), 455-463.
Hooper, D. C., & Jacoby, G. A. (2016). Mechanisms of action of quinolones. *Clinical Infectious Diseases*, 42(Supplement 2), S47-S52.
Levy, S.B. (2011). Antibiotic resistance: Causes and responses. *FEMS Microbiology Reviews*, 35(3), 446-455.
Wilson, K., & Walker, J. (2020). *Principles and Techniques of Biochemistry and Molecular Biology*. Cambridge University Press.